Ping An Securities Research Report pointed out that Maipu Medical's performance grew steadily, and there was a significant increase in Q2 compared to the previous month. 2026H1 achieved net profit of 56.58 million yuan, yoy +19.62%. Looking at Q2 alone, the company achieved net profit of 35.87 million yuan, yoy +55.01%. The company is a leading enterprise in the field of neurosurgery. It has remarkable innovation advantages. It is developing simultaneously at home and abroad, and new products are expected to continue to open up room for growth. Considering issues such as the pace of collection and implementation, according to the interim report, we adjusted and forecast that the company would achieve net profit of 1.45/1.81/221 million yuan in 2026-28. Due to the unchanged trend of the company's domestic and foreign product sales, the business trend continues to improve. We are optimistic about the company's long-term development and maintain the “recommended” rating.

Ping An Securities Research Report pointed out that Maipu Medical's performance grew steadily, and there was a significant increase in Q2 compared to the previous month. 2026H1 achieved net profit of 56.58 million yuan, yoy +19.62%. Looking at Q2 alone, the company achieved net profit of 35.87 million yuan, yoy +55.01%. The company is a leading enterprise in the field of neurosurgery. It has remarkable innovation advantages. It is developing simultaneously at home and abroad, and new products are expected to continue to open up room for growth. Considering issues such as the pace of collection and implementation, according to the interim report, we adjusted and forecast that the company would achieve net profit of 1.45/1.81/221 million yuan in 2026-28. Due to the unchanged trend of the company's domestic and foreign product sales, the business trend continues to improve. We are optimistic about the company's long-term development and maintain the “recommended” rating.